2026-04-14T09:43:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4702212025-08-31T16:32:20Zcom_2072_98col_2072_378192

Determinants of long-term survival in late HIV presenters : The prospective PISCIS cohort study Martin-Iguacel, Raquel Reyes-Urueña, Juliana Bruguera Riera, Andreu Aceitón, Jordi Díaz, Yesika Moreno-Fornés, Sergio Domingo, Pere Burgos, Joaquín Tiraboschi, Juan Manuel Johansen, Isik Somuncu Álvarez, Hortensia Miró, Josep M. Casabona-Barbarà, Jordi Llibre, Josep M.. Universitat Autònoma de Barcelona Delayed HIV diagnosis HIV Integrase inhibitors Immune recovery Immune response Late presenters Mortality Late HIV diagnosis (i.e CD4≤350 cells/µL) is associated with poorer outcomes. However, determinants of long-term mortality and factors influencing immune recovery within the first years after antiretroviral treatment (ART) initiation are poorly defined. From PISCIS cohort, we included all HIV-positive adults, two-year survivors after initiating ART between 2005-2019. The primary outcome was all-cause mortality according to the two-year CD4 count. We used Poisson regression. The secondary outcome was incomplete immune recovery (i.e., two-year CD4<500 cells/µL). We used logistic regression and propensity score matching. We included 2,719 participants (16593·1 person-years): 1441 (53%) late presenters (LP) and 1278 non-LP (1145 non-LP with two-year CD4 count >500 cells/µL, reference population). Overall, 113 patients (4·2%) died. Mortality was higher among LP with two-year CD4 count 200-500 cells/µL (aMRR 1·95[95%CI:1·06-3·61]) or <200 cells/µL (aMRR 4·59[2·25-9·37]). Conversely, no differences were observed in participants with two-year CD4 counts >500 cells/µL, regardless of being initially LP or non-LP (aMRR 1·05[0·50-2·21]). Mortality rates within each two-year CD4 strata were not affected by the initial CD4 count at ART initiation (test-interaction, p = 0·48). The stronger factor influencing immune recovery was the CD4 count at ART initiation. First-line integrase-inhibitor-(INSTI)-based regimens were associated with reduced mortality compared to other regimens (aMRR 0·54[0·31-0·93]) and reduced risk of incomplete immune recovery in LP (aOR 0·70[0·52-0·95]). Two-year immune recovery is a good early predictor of long-term mortality in LP after surviving the first high-risk 2 years. Nearly half experienced a favorable immune recovery with a life expectancy similar to non-LP. INSTI-based regimens were associated with higher rates of successful immune recovery and better survival compared to non-INSTI regimens. Southern-Denmark University, Danish AIDS-foundation, and Region of Southern Denmark. 2022 Article https://ddd.uab.cat/record/282706 urn:10.1016/j.eclinm.2022.101600 urn:oai:ddd.uab.cat:282706 urn:pmcid:PMC9358427 urn:pmc-uid:9358427 urn:oai:pubmedcentral.nih.gov:9358427 urn:pmid:35958520 urn:oai:egreta.uab.cat:publications/e8838ff4-90e3-4130-ba61-13c4dee5b77a eng EClinicalMedicine ; Vol. 52 (august 2022) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf